International Isotopes posts results for 2003
Sales at International Isotopes Inc. (I3) dipped slightly to $2.1 million, compared with $2.2 million in 2002.
I3 blamed the decrease to the delay of a major cobalt sale from November 2003 into 2004 "because of circumstances beyond [the company's] control." If the sale has occurred, I3 said 2003 sales would have risen to approximately $2.4 million. The deal was completed on Feb. 15.
I3's net loss from continuing operations was $554,749 in 2003, compared with $350,453 in 2002. The hike was due to increases in R&D costs, marketing consultant fees and increasing staff size.
In 2003, I3 achieved a 24 percent advance in sales of nuclear medicine reference and calibration standards, while it noted a 30 percent decline in support services revenues.
I3 manufactures nuclear medicine calibration and reference standards and provides a selection of radioisotopes and radiochemicals for medical devices, calibration, clinical research, life sciences and industrial applications.
I3 blamed the decrease to the delay of a major cobalt sale from November 2003 into 2004 "because of circumstances beyond [the company's] control." If the sale has occurred, I3 said 2003 sales would have risen to approximately $2.4 million. The deal was completed on Feb. 15.
I3's net loss from continuing operations was $554,749 in 2003, compared with $350,453 in 2002. The hike was due to increases in R&D costs, marketing consultant fees and increasing staff size.
In 2003, I3 achieved a 24 percent advance in sales of nuclear medicine reference and calibration standards, while it noted a 30 percent decline in support services revenues.
I3 manufactures nuclear medicine calibration and reference standards and provides a selection of radioisotopes and radiochemicals for medical devices, calibration, clinical research, life sciences and industrial applications.